The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade
Open accessAbstract
The stimulator of interferon genes (STING) signaling pathway is a critical link between innate and adaptive immunity, and induces anti-tumor immune responses. STING is expressed in vasculatures, but its role in tumor angiogenesis has not been elucidated. Here we investigated STING-induced tumor vascular remodeling and the potential of STING-based combination immunotherapy. Endothelial STING expression was correlated with enhanced T-cell infiltration and prolonged survival in human colon and breast cancer. Intratumoral STING activation with STING agonists (cGAMP or RR-CDA) normalized tumor vasculatures in implanted and spontaneous cancers, but not in STING-deficient mice. These were mediated by upregulation of type I/II interferon genes and vascular stabilizing genes (e.g., Angpt1, Pdgfrb, and Col4a). STING in non-hematopoietic cells is as important as STING in hematopoietic cells to induce a maximal therapeutic efficacy of exogenous STING agonist. Vascular normalizing effects of STING agonists were dependent on type I interferon signaling and CD8+ T cells. Notably, STING-based immunotherapy was maximally effective when combined with VEGFR2 blockade and/or immune checkpoint blockade (αPD-1 or αCTLA-4), leading to complete regression of immunotherapy-resistant tumors. Our data show that intratumoral STING activation can normalize tumor vasculature and the tumor microenvironment, providing a rationale for combining STING-based immunotherapy and anti-angiogenic therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Ishikawa, H., & Barber, G. N. (2008) · Nature · doi:10.1038/nature07317 · Cited by 3,576
Regulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297
Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing
Chen, Q., Sun, L., & Chen, Z. J. (2016) · Nature Immunology · doi:10.1038/ni.3558 · Cited by 2,333
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
Microenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847 · cited 2×
“Environmental signals cause macrophages to undergo reversible phenotypic switching into either M1- or M2-like macrophages, which are proposed to suppress and promote tumor angiogenesis, respectively (13, 36, 37).”
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
Activated STING in a Vascular and Pulmonary Syndrome
Liu, Y., Jesus, A. A., Marrero, B., Yang, D., Ramsey, S. E., Montealegre Sanchez, G. A., Tenbrock, K., Wittkowski, H., Jones, O. Y., Kuehn, H. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312625 · Cited by 1,412
STING: infection, inflammation and cancer.
Barber, G. N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3921 · Cited by 1,313
Lin, E. Y., Jones, J. G., Li, P., Zhu, L., Whitney, K. D., Muller, W. J., & Pollard, J. W. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63568-7 · Cited by 1,107
Management of toxicities of immune checkpoint inhibitors
Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.001 · Cited by 854
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., Sheng, K., Dobrolecki, L. E., Zhang, X., Putluri, N., et al. (2017) · Nature · doi:10.1038/nature21724 · Cited by 841 · cited 1×
“CD8 + cytotoxic T cells and Th1 cells secrete IFN-γ , which inhibits tumor angiogenesis by restraining endothelial cell proliferation and upregulating cytokine-encoding genes (e.g., CXCL9, CXCL10, and CXCL11) that stimulate pericyte recruitment (13, 18).”
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820 · cited 1×
“The dynamic interplay between endothelium and immune cells is important for immune cell trafficking across the endothelial barrier and determines the quality and amplitude of anticancer immune responses (16–19).”
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
Fu, J., Kanne, D. B., Leong, M., Glickman, L. H., McWhirter, S. M., Lemmens, E., Mechette, K., Leong, J. J., Lauer, P., Liu, W., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4306 · Cited by 720
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Khan, K. A., & Kerbel, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.9 · Cited by 657
Adaptive Immune Resistance: How Cancer Protects from Immune Attack
Ribas, A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0563 · Cited by 613
STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity
Demaria, O., De Gassart, A., Coso, S., Gestermann, N., Di Domizio, J., Flatz, L., Gaide, O., Michielin, O., Hwu, P., Petrova, T. V., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512832112 · Cited by 578
Sidky, Y. A., & Borden, E. C. (1987) · PubMed · Cited by 494
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment
Gajewski, T. F. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.011 · Cited by 488
Mandai, M., Hamanishi, J., Abiko, K., Matsumura, N., Baba, T., & Konishi, I. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0224 · Cited by 395
Albini, A., Bruno, A., Noonan, D. M., & Mortara, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00527 · Cited by 392
Terawaki, S., Chikuma, S., Shibayama, S., Hayashi, T., Yoshida, T., Okazaki, T., & Honjo, T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003208 · Cited by 342
Park, J.-S., Kim, I.-K., Han, S., Park, I., Kim, C., Bae, J., Oh, S. J., Lee, S., Kim, J. H., Woo, D.-C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.018 · Cited by 327 · cited 2×
“Moreover, glucose transporter 1 (GLUT1) level was analyzed as a hypoxia marker as previously described (21, 27), revealing a 46% decrease in intratumoral hypoxia after RR-CDA injection compared with controls (Figure 3, D–F).”
Self-citationTumour ischaemia by interferon-γ resembles physiological blood vessel regression
Kammertoens, T., Friese, C., Arina, A., Idel, C., Briesemeister, D., Rothe, M., Ivanov, A., Szymborska, A., Patone, G., Kunz, S., et al. (2017) · Nature · doi:10.1038/nature22311 · Cited by 269
Baird, J. R., Friedman, D., Cottam, B., Dubensky, T. W., Kanne, D. B., Bambina, S., Bahjat, K., Crittenden, M. R., & Gough, M. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3619 · Cited by 257
Ohkuri, T., Ghosh, A., Kosaka, A., Zhu, J., Ikeura, M., David, M., Watkins, S. C., Sarkar, S. N., & Okada, H. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0099 · Cited by 252
Marabelle, A., Andtbacka, R., Harrington, K., Melero, I., Leidner, R., de Baere, T., Robert, C., Ascierto, P. A., Baurain, J. F., Imperiale, M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy423 · Cited by 215
Carman, C. V., & Martinelli, R. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00603 · Cited by 207
Corrales, L., & Gajewski, T. F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1362 · Cited by 197
Ager, C. R., Reilley, M. J., Nicholas, C., Bartkowiak, T., Jaiswal, A. R., & Curran, M. A. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0049 · Cited by 180
Foote, J. B., Kok, M., Leatherman, J. M., Armstrong, T. D., Marcinkowski, B. C., Ojalvo, L. S., Kanne, D. B., Jaffee, E. M., Dubensky, T. W., & Emens, L. A. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0284 · Cited by 170
Chon, H. J., Lee, W. S., Yang, H., Kong, S. J., Lee, N. K., Moon, E. S., Choi, J., Han, E. C., Kim, J. H., Ahn, J. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1932 · Cited by 158 · cited 1×
“…model, MMTV-PyMT , which has more mature tumor vasculatures and abundant stromal cells and is therefore a reliable representative of human breast cancer (30, 31), to further validate the efficacy of STING activation in combination with VEGFR2 blockade and immune checkpoint inhibition (Figure 10A).”
Self-citationVascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption
Kim, C., Yang, H., Fukushima, Y., Saw, P. E., Lee, J., Park, J.-S., Park, I., Jung, J., Kataoka, H., Lee, D., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.010 · Cited by 131
Self-citationYang, H., Kim, C., Kim, M.-J., Schwendener, R. A., Alitalo, K. K., Heston, W., Kim, I., Kim, W., & Koh, G. Y. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-36 · Cited by 114
Self-citationA Milestone Review on How Macrophages Affect Tumor Growth
Caux, C., Ramos, R. N., Prendergast, G. C., Bendriss‐Vermare, N., & Ménétrier‐Caux, C. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-2631 · Cited by 103
Zheng, H., Qian, J., Carbone, C. J., Leu, N. A., Baker, D. P., & Fuchs, S. Y. (2011) · Blood · doi:10.1182/blood-2011-06-359745 · Cited by 74
Rationale for stimulator of interferon genes–targeted cancer immunotherapy
Vargas, T. R., Benoit-Lizon, I., & Apétoh, L. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.028 · Cited by 70
Jia, H., Thelwell, C., Dilger, P., Bird, C., Daniels, S., & Wadhwa, M. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.01.039 · Cited by 59
Reprogramming Tumor Blood Vessels for Enhancing Immunotherapy
Schmittnaegel, M., & Palma, M. D. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.10.002 · Cited by 58
CD4 + T Cell Activation and Vascular Normalization: Two Sides of the Same Coin?
Palma, M. D., & Jain, R. K. (2017) · Immunity · doi:10.1016/j.immuni.2017.04.015 · Cited by 54
STING expression and response to treatment with STING ligands in premalignant and malignant disease
Baird, J. R., Feng, Z., Xiao, H., Friedman, D. J., Cottam, B., Fox, B. A., Kramer, G. F., Leidner, R. S., Bell, R. B., Young, K. H., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187532 · Cited by 45
Continuous Delivery of IFN-β Promotes Sustained Maturation of Intratumoral Vasculature
Dickson, P. V., Hamner, J. B., Streck, C. J., Ng, C. Y., McCarville, M. B., Calabrese, C. R., Gilbertson, R. J., Stewart, C. F., Wilson, C., Gaber, M. W., et al. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0259 · Cited by 41
Jang, J. Y., Choi, S. Y., Park, I., Park, D. Y., Choe, K., Kim, P., Kim, Y. K., Lee, B., Hirashima, M., Kubota, Y., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607341 · Cited by 26
Efficacy and Toxic Effects of Cancer Immunotherapy Combinations—A Double-edged Sword
Tang, C. Z., Jiang, W., & Yap, T. A. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4606 · Cited by 20
Cited by
Targeting STAT3 in Cancer Immunotherapy
Zou, S., Tong, Q., Liu, B., Huang, W., Tian, Y., & Fu, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01258-7 · Cited by 1,050
Turning Cold into Hot: Firing up the Tumor Microenvironment
Duan, Q., Zhang, H., Zheng, J., & Zhang, L. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.022 · Cited by 934
The role of ubiquitination in tumorigenesis and targeted drug discovery
Deng, L., Meng, T., Chen, L., Wei, W., & Wang, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0107-0 · Cited by 744
Lee, W. S., Yang, H., Chon, H. J., & Kim, C. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00500-y · Cited by 688
Self-citationSTING: a master regulator in the cancer-immunity cycle
Zhu, Y., An, X., Zhang, X., Qiao, Y., Zheng, T., & Li, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1087-y · Cited by 431
Metadata
- Authors
- Yang, H., Lee, W. S., Kong, S. J., Kim, C. G., Kim, J. H., Chang, S. K., Kim, S., Kim, G., Chon, H. J., & Kim, C.
- Venue
- Journal of Clinical Investigation
- Published
- 2019-09-09
- Volume
- 129
- Issue
- 10
- Pages
- 4350-4364
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2963305393
- Cited by
- 313
- References
- 47
- FWCI
- 9.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.